Top

European Journal of Medical Research

Published in:

01-12-2011 | Research

The non-invasive ¹³C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis

Authors: M Banasch, M Ellrichmann, A Tannapfel, WE Schmidt, O Goetze

Published in: European Journal of Medical Research | Issue 6/2011

Abstract

Introduction

Mitochondrial dysfunction plays a central role in the general pathogenesis of non-alcoholic fatty liver disease (NAFLD), increasing the risk of developing steatosis and subsequent hepatocellular inflammation. We aimed to assess hepatic mitochondrial function by a non-invasive ¹³C-methionine breath test (MeBT) in patients with histologically proven NAFLD.

Methods

118 NAFLD-patients and 18 healthy controls were examined by MeBT. Liver biopsy specimens were evaluated according to the NASH scoring system.

Results

Higher grades of NASH activity and fibrosis were independently associated with a significant decrease in cumulative ¹³C-exhalation (expressed as cPDR(%)). cPDR_1.5h was markedly declined in patients with NASH and NASH cirrhosis compared to patients with simple steatosis or borderline diagnosis (cPDR1.5h: 3.24 ± 1.12% and 1.32 ± 0.94% vs. 6.36 ± 0.56% and 4.80 ± 0.88% respectively; p < 0.001). ¹³C-exhalation further declined in the presence of advanced fibrosis which was correlated with NASH activity (r = 0.36). The area under the ROC curve (AUROC) for NASH diagnosis was estimated to be 0.87 in the total cohort and 0.83 in patients with no or mild fibrosis (F0-1).

Conclusion

The ¹³C-methionine breath test indicates mitochondrial dysfunction in non-alcoholic fatty liver disease and predicts higher stages of disease activity. It may, therefore, be a valuable diagnostic addition for longitudinal monitoring of hepatic (mitochondrial) function in non-alcoholic fatty liver disease.

McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004,8(3):521–33. viii 10.1016/j.cld.2004.04.004PubMedCrossRef

Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006,40(3 Suppl 1):S5–10.PubMed

Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006,43(2 Suppl 1):S99-S112.PubMedCrossRef

Begriche K, Igoudjil A, Pessayre D, Fromenty B: Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006,6(1):1–28. 10.1016/j.mito.2005.10.004PubMedCrossRef

Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al.: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999,31(3):430–4. 10.1016/S0168-8278(99)80033-6PubMedCrossRef

Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et al.: Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003,38(4):999–1007.PubMedCrossRef

Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, et al.: Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005,128(5):1381–90. 10.1053/j.gastro.2005.02.001PubMedCrossRef

Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, et al.: TNF-alpha downregulates eNoS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006,116(10):2791–8.PubMedCentralPubMedCrossRef

Wei Y, Rector RS, Thyfault JP, Ibdah JA: Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008,14(2):193–9. 10.3748/wjg.14.193PubMedCentralPubMedCrossRef

10.

Milazzo L, Piazza M, Sangaletti O, Gatti N, Cappelletti A, Adorni F, et al.: [¹³ C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2005,55(1):84–9.PubMedCrossRef

11.

Armuzzi A, Marcoccia S, Zocco MA, De Lorenzo A, Grieco A, Tondi P, et al.: Non-Invasive assessment of human hepatic mitochondrial function through the ¹³ C-methionine breath test. Scand J Gastroenterol 2000,35(6):650–3. 10.1080/003655200750023633PubMedCrossRef

12.

Spahr L, Negro F, Leandro G, Marinescu O, Goodman KJ, Rubbia-Brandt L, et al.: Impaired hepatic mitochondrial oxidation using the ¹³ C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. Med Sci Monit 2003,9(1):CR6–11.PubMed

13.

Banasch M, Goetze O, Hollborn I, Hochdorfer B, Bulut K, Schlottmann R, et al.: ¹³ C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. J Acquir Immune Defic Syndr 2005,40(2):149–54. 10.1097/01.qai.0000179465.48571.d5PubMedCrossRef

14.

Banasch M, Goetze O, Knyhala K, Potthoff A, Schlottmann R, Kwiatek MA, et al.: Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. Aids 2006,20(11):1554–6. 10.1097/01.aids.0000237373.38939.14PubMedCrossRef

15.

Banasch M, Emminghaus R, Ellrichmann M, Schmidt WE, Goetze O: Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test. Aliment Pharmacol Ther 2008,28(4):443–9. 10.1111/j.1365-2036.2008.03745.xPubMedCrossRef

16.

Banasch M, Goetze O, Schmidt WE, Meier JJ: Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int 2007,27(8):1152–5. 10.1111/j.1478-3231.2007.01555.xPubMedCrossRef

17.

Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F: Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006,111(2):135–43. 10.1042/CS20050346CrossRef

18.

Schmilovitz-Weiss H, Niv Y, Pappo O, Halpern M, Sulkes J, Braun M, et al.: The ¹³ C-Caffeine Breath Test Detects Significant Fibrosis in Patients With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2008,42(4):408–412. 10.1097/MCG.0b013e318046ea65PubMedCrossRef

19.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005,41(6):1313–21. 10.1002/hep.20701PubMedCrossRef

20.

Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al.: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008,40(5):371–8. 10.1016/j.dld.2007.10.019PubMedCrossRef

21.

Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE: In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease. Hepatology 2006,44(1):27–33.PubMedCrossRef

22.

Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ: Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009,50(4):1072–8. 10.1002/hep.23050PubMedCentralPubMedCrossRef

23.

Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, et al.: Cytokeratin 18 fragment levels as a non-invasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008,6(11):1249–54. 10.1016/j.cgh.2008.07.016PubMedCentralPubMedCrossRef

24.

Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA, et al.: A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005,54(7):1926–33. 10.2337/diabetes.54.7.1926PubMedCrossRef

25.

Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003,100(14):8466–71. 10.1073/pnas.1032913100PubMedCentralPubMedCrossRef

26.

Banasch M, Knyhala K, Kollar S, Serova K, Potthoff A, Schlottmann R, et al.: Disease- and treatment-related predictors of hepatic mitochondrial dysfunction in chronic HIV infection assessed by non-invasive (13)C-methionine breath test diagnostic. European Journal of Medical Research 2008,13(9):401–8.PubMed

27.

Banasch M, Frank J, Serova K, Knyhala K, Kollar S, Potthoff A, et al.: Impact of antiretroviral treatment on (13)C-methionine metabolism as a marker of hepatic mitochondrial function: a longitudinal study. HIV Med 2010, in press.

Title: The non-invasive 13C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis
Authors: M Banasch
M Ellrichmann
A Tannapfel
WE Schmidt
O Goetze
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 6/2011
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-16-6-258

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The non-invasive ¹³C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

Management of pelvic lymphoceles after radical prostatectomy: A multicentre community based study

Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure

The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract

Induction maintenance concept for HAART as initial treatment in HIV infected infants

Comparative examination of subcutaneous tissue reaction to high molecular materials in medical use

Immunohistochemical localization of notch signaling molecules in ameloblastomas